Abstract:A series of 10-amino-6,8,12,12a-tetrahydro-5H-thiazolo[4',5':4,5]pyrido[2,1-a] isoquinolines with substituent hydroxyl or methoxyl groups at C2 and C3 positions of the benzene ring were designed and synthesized. These compounds are 2-aminothiazole bioisosteres of the natural product stepholidine (SPD). Radioligand binding assays showed that compounds 10a, 10b, 10c and 12b had moderate binding affinity and activity for the D1 receptor, as well as high selectivity over the D2 receptor. Among them, 10c exhibited moderate D3 receptor binding affinity. 10a with an amino group in position 10 showed higher affinities toward D3 receptor compared to those without an amino group. In silico docking analysis of active ligands was performed to explain the result of binding assays and analyze structure-activity relationship for further structure optimization. Our analysis suggested that besides the salt bridge interaction formed by the conserved D3.32 with the protonated nitrogen of ligands and the hydrogen bonds formed by S5.42 with 2-hydroxyl group and S5.46 with 3-methoxyl group, a hydrogen bond formed between S188 located on the second extracellular loop (ECL2) and the nitrogen in the thiazole ring was critical to the affinity of this series of compounds for the D1 receptor, which was in agreement with the interaction mode between SPD and the D1 receptor. Â Our results suggested that the introduction of thiazole ring changes the pharmacological profile of SPD and the optimized compounds have high selective activity to D1 receptor over D2 receptor. These thiazole-SPD-derivative compounds have potential clinical use in Parkinsonâ€™s disease and other conditions related to dopamine receptors.

Identification of benzoxazole analogs as novel, S1P3 sparing S1P1 agonists

Discovery of Novel 1,2,4-Thiadiazole Derivatives As Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).

Discovery of Thiadiazole Amides As Potent, S1p(3)-Sparing Agonists of Sphingosine-1-Phosphate 1 (s1p(1)) Receptor

Indole-propionic acid derivatives as potent, S1P 3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P 1) receptor agonists

Discovery and Identification of Novel 5-Hydroxy-4 H -benzo[1,4]oxazin-3-one Derivatives as Potent β 2 -Adrenoceptor Agonists through Structure-Based Design, Synthesis, and Biological Evaluation

Design,Synthesis and Biological Evaluation of Potent and Selective S1PR1 Agonists for the Treatment of Ulcerative Colitis

Synthesis and Biological Evaluation of 1, 2, 4-Oxadiazole Derivatives As Novel Gpr119 Agonists

Synthesis and Biological Evaluation of Novel Benzamide Derivatives As Potent Smoothened Antagonists.

Identification of Novel 2-(Benzo[d]isoxazol-3-yl)-2-oxo-n-phenylacetohydrazonoyl Cyanide Analoguesas Potent EPAC Antagonists.

Design, Synthesis, and in Vitro Bioactivity Evaluation of Fluorine-Containing Analogues for Sphingosine-1-phosphate 2 Receptor.

Design, Synthesis and Evaluation of Benzo[a]thieno[3,2-G]quinolizines As Novel L-Spd Derivatives Possessing Dopamine D1, D2 and Serotonin 5-HT1A Multiple Action Profiles.

Pyrazolidine-3,5-dione Derivatives As Potent Non-Steroidal Agonists of Farnesoid X Receptor: Virtual Screening, Synthesis, and Biological Evaluation.

Design, Synthesis And 3d-Qsar Study Of 2-[N '-(2-Aryloxyethyl)Piperazinomethyl]-Benzoxazole Series As Alpha(1)-Adrenoceptor Antagonists

SAR Studies of N-[2-(1H-Tetrazol-5-yl)phenyl]benzamide Derivatives As Potent G Protein-Coupled Receptor-35 Agonists.

3D-QSAR Studies on Thiazolidin-4-one S1P1 Receptor Agonists by CoMFA and CoMSIA

Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies of 10-Amino-3-methoxy-6,8,12,12a-tetrahydro-5h-thiazolo[4',5':4,5]Pyrido[2,1-a]isoquinolin-2-ols As Novel Dopamine D1 Receptor Inhibitors

Qsar of Pyrazole Oxadiazole Derivatives As S1p1 Agonists Studied by Comfa, Comsia and Docking

Discovery of N-cyclobutylaminoethoxyisoxazole Derivatives As Novel Sigma-1 Receptor Ligands with Neurite Outgrowth Efficacy in Cells

Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy

Design, Synthesis, and Structure-Activity-relationship of a Novel Series of CXCR4 Antagonists.

Discovery of (S)-N-(2-amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6h)-yl)ethyl)benzamide As Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.